Prosecution Insights
Last updated: November 04, 2026
Application No. 18/351,305

COMPOSITIONS AND METHODS FOR SOFT TISSUE AUGMENTATION18348273

Final Rejection §103
Filed
Jul 12, 2023
Priority
Jan 15, 2021 — provisional 63/138,267 +2 more
Examiner
MEYERS, ELIZABETH ANNE
Art Unit
1617
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Metisculpt Inc.
OA Round
2 (Final)
21%
Grant Probability
At Risk
3-4
OA Rounds
0m
Est. Remaining
99%
With Interview

Examiner Intelligence

Grants only 21% of cases
21%
Career Allowance Rate
4 granted / 19 resolved
-38.9% vs TC avg
Strong +94% interview lift
Without
With
+93.8%
Interview Lift
resolved cases with interview
Typical timeline
3y 1m
Avg Prosecution
47 currently pending
Career history
92
Total Applications
across all art units

Statute-Specific Performance

§101
1.0%
-39.0% vs TC avg
§103
41.9%
+1.9% vs TC avg
§102
9.8%
-30.2% vs TC avg
§112
28.9%
-11.1% vs TC avg
Black line = Tech Center average estimate • Based on career data from 19 resolved cases

Office Action

§103
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Status of the Claims Claims 1-6, 8, 10-16, 19, 23-25, 27, 29-30, 32, and 37-41 are pending. Claims 7, 9, 17-18, 20-22, 26, 28, 31, and 33-36 are cancelled. Claims 1-6, 8, and 37-41 are under current examination. Claims 10-16, 19, 23-25, 27, 29-30, and 32 are withdrawn. Withdrawn Claim Objections and Rejections All objections and rejections of claims 7, 20, and 21 are moot because the claims are cancelled in the amendments to the claims filed 6/29/2026. All objections to claims 2-6 are withdrawn in view of the amendments to the claims filed 6/29/2026. All rejections under 35 U.S.C. 112(b) pertaining to claims 2, 5, and 6 are withdrawn in view of the amendments to the claims filed 6/29/2026. All non-statutory double patenting rejections over U.S. Patent No. 6,231,605 are withdrawn in view of the amendments to the claims filed 6/29/2026. All rejections not reiterated have been withdrawn. Claim Rejections - 35 USC § 103 Applicant’s amendments to the claims filed 6/29/2026 have necessitated the new grounds of rejection. In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis (i.e., changing from AIA to pre-AIA ) for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status. The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action: A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made. The factual inquiries for establishing a background for determining obviousness under 35 U.S.C. 103 are summarized as follows: 1. Determining the scope and contents of the prior art. 2. Ascertaining the differences between the prior art and the claims at issue. 3. Resolving the level of ordinary skill in the pertinent art. 4. Considering objective evidence present in the application indicating obviousness or nonobviousness. This application currently names joint inventors. In considering patentability of the claims the examiner presumes that the subject matter of the various claims was commonly owned as of the effective filing date of the claimed invention(s) absent any evidence to the contrary. Applicant is advised of the obligation under 37 CFR 1.56 to point out the inventor and effective filing dates of each claim that was not commonly owned as of the effective filing date of the later invention in order for the examiner to consider the applicability of 35 U.S.C. 102(b)(2)(C) for any potential 35 U.S.C. 102(a)(2) prior art against the later invention. Claims 1-5, 8, and 37 are rejected under 35 U.S.C. 103 as being unpatentable over Sinclair (WO2020131513, publication year: 2020). Determination of the scope and the content of the prior art (MPEP §2141.01) Regarding claim 1, Sinclair teaches hydrogel compositions that comprise a polysaccharide and polyzwitterionic component (Claim 1). The polyzwitterionic component that may include hydrophilic repeat units of polyvinyl alcohol (Claim 7). The hydrogel composition may be used to provide materials or products with non-Newtonian behavior such as pseudoplastic and Bingham plastic properties [00146]. In some embodiments, the hydrogel composition may be used to provide an injectable or spreadable material for biomedical applications, particularly in applications requiring non-Newtonian fluid properties and high biocompatibility, such as injectable or spreadable materials capable of mechanical support, such as those used in reconstructive surgery, blood vessel prostheses, skin repair devices, cochlear replacements, injectable vitreous substances, artificial cartilage, artificial fat, collagen mimics and other soft tissue-mimics or supports [00150]. The hydrogel composition may further comprise an aqueous liquid [00133]. Claim 1 is a product-by-process claim. According to MPEP 2113: product-by-process claims are not limited to the manipulations of the recited steps, only the structure implied by the steps. “The structure implied by the process steps should be considered when assessing the patentability of product-by-process claims over the prior art”; therefore, the Examiner considers the teaching of Sinclar to read on the limitations of the instant claim 1. Regarding claim 2, Sinclair teaches that the hydrogel composition may be used to provide materials or products with non-Newtonian behavior such as shear thinning (pseudoplastic) and Bingham plastic properties [00146]. Regarding claim 3, Sinclair teaches that the hydrogel composition may be included in packaged product comprising a syringe loaded with the hydrogel composition and a needle [00137]. Regarding claim 4, Sinclair teaches that the composition may be transferred or injected into a casting mold prior to UV-crosslinking [00113]. The composition may be expected to create a supportive tissue-mimetic structure after injection or implantation in the human body [00127]. Regarding claim 5, Sinclair teaches that the polyzwitterionic component may have a molecular weight of 1 to about 10,000 [0011]. Regarding claim 8, Sinclair teaches that the network structure may be supplemented or blended with one or more additives of cosmetic or therapeutic utility [0016]. Regarding claim 37, Sinclair teaches that the syringe comprising the hydrogel composition may be packaged or fitted with a needle of any size that is appropriate for injecting the hydrogel into the soft tissue of interest, such as a needle with about a 25, 27, or 30 gauge [00137]. Ascertainment of the Difference Between Scope of the Prior Art and the Claims (MPEP §2141.02) Sinclair does not teach a single embodiment or example meeting all limitation of the invention of claims 1-5, 8, and 37. Finding of a Prima Facie Obviousness Rationale and Motivation (MPEP §2142-2143) Within the broader scope of Sinclair all of the limitations of the invention of claims 1-5, 8, and 37 are met. It would have been prima facie obvious for one having ordinary skill in the art to choose the limitations in the instant claims from those disclosed by Sinclair and arrive at this conclusion because such was contemplated by Sinclair. Claims 38 and 39 are rejected under 35 U.S.C. 103 as being unpatentable over Sinclair (WO2020131513, publication year: 2020), as applied to claims 1-5, 8, and 37 above, and further in view of Ku (U.S. Patent No. 6,231,605, issue year: 2001, cited in the IDS filed 10/12/2023, of record). Determination of the scope and the content of the prior art (MPEP §2141.01) Regarding claims 38 and 39, Sinclair teaches that the polyzwitterionic component may have a molecular weight of 1 to about 10,000 [0011]. Ascertainment of the Difference Between Scope of the Prior Art and the Claims (MPEP §2141.02) Regarding claims 38, and 39, Sinclair does not teach a molecular weight of the polyvinyl alcohol within the range embraced by the instant claims . However, this deficiency is cured by Ku. Ku teaches a non-dehydrated polyvinyl alcohol (PVA) hydrogel construct which is capable of being molded into a number of shapes, and which is capable of retaining a wide range of mechanical strengths for various applications (col. 2 lines 32-37). The hydrogel tissue replacement construct is especially useful in surgical and other medical applications as an artificial material for replacing and reconstructing soft tissues in humans and other mammals (col. 3 lines 11-14). The molecular weight of the polyvinyl alcohol can be chosen depending upon the particular application envisioned for the hydrogel. Generally, increasing the molecular weight of the polyvinyl alcohol increases the tensile strength and tensile stiffness, and thereby improves the properties of constructs such as vascular grafts, wherein increased strength is desirable. In other applications, lower molecular weight polyvinyl alcohol can be employed because lower tensile strength and lower tensile stiffness are desirable (col. 5 lines 1-13). Finding of a Prima Facie Obviousness Rationale and Motivation (MPEP §2142-2143) Regarding the molecular weight of polyvinyl alcohol as specified in claims 38 and 39, MPEP 2144.05 states: Generally, differences in concentration or temperature will not support the patentability of subject matter encompassed by the prior art unless there is evidence indicating such concentration or temperature is critical. “[W]here the general conditions of a claim are disclosed in the prior art, it is not inventive to discover the optimum or workable ranges by routine experimentation.” In re Aller, 220 F.2d 454, 456, 105 USPQ 233, 235 (CCPA 1955). Furthermore, Ku teaches that the molecular weight of polyvinyl alcohol present in hydrogel compositions has a direct effect on the tensile strength of the composition. The Applicants' specification provides no evidence that the selected molecular weight ranges in claims 38 and 39 was not due to routine optimization and/or that the results should be considered unexpected compared to the prior art. Due to the direct effect of molecular weight on the tensile strength of the hydrogel composition, it would have been prima facie obvious to a person of ordinary skill in the art at the time of the invention to combine these teachings and alter the molecular weight based on the desired properties of the composition. One of ordinary skill in the art would have been motivated to change the molecular weight as this could be expected to be advantageous for achieving the desired tensile strength of the final composition. Claims 6, 40, and 41 are rejected under 35 U.S.C. 103 as being unpatentable over Sinclair (WO2020131513, publication year: 2020), as applied to claims 1-5, 8, and 37 above, and further in view of Gaaz et. al. (Molecules, pg. 22833-22847; publication year: 2015). Determination of the scope and the content of the prior art (MPEP §2141.01) Regarding claims 6, 40, and 41, Sinclair teaches the relevant limitations of claim 1 above. Ascertainment of the Difference Between Scope of the Prior Art and the Claims (MPEP §2141.02) Regarding claims 6, 40, and 41, Sinclair does not teach a degree of hydrolysis of the polyvinyl alcohol. However, this deficiency is cured by Gaaz. Gaaz teaches that the hydrolysis levels of PVA range from what is considered a typical value of 80% to reach more than 99%. Nearly fully hydrolyzed forms result in forming PVA hydrogels with tunable properties through crosslinking the linear polymers, which subsequently result in polymer (gel)-fluid (sol) species. Polymer contents affect the physical status of the resulting material: low polymer content results in a soft material because the fluid moves freely through the matrix, whereas a higher polymer content results in considerably stiffening or strengthening of the material’s matrix (pg. 22835, 2. Chemical Structure of PVA). Finding of a Prima Facie Obviousness Rationale and Motivation (MPEP §2142-2143) The degree of hydrolysis of polyvinyl alcohol is clearly a result effective parameter that a person of ordinary skill in the art would routinely optimize. Optimization of parameters is a routine practice that would be obvious for a person of ordinary skill in the art to employ and would reasonably expect success. It would have been customary for an artisan of ordinary skill to determine the optimal degree of hydrolysis in order to best achieve the desired results as such would provide advantageous physical characteristics of the hydrogel. It would have been prima facie obvious to one of ordinary skill in the art at the time of the invention to engage in routine experimentation to determine optimal or workable ranges that produce expected results. Where the general conditions of a claim are disclosed in the prior art, it is not inventive to discover the optimum or workable ranges by routine experimentation. In re Aller, 220 F. 2d 454, 105 USPQ 233 (CCPA 1955). In the instant case, Gaaz teaches that an increased degree of hydrolysis of PVA yields a hydrogel with increased stiffening or strengthening of the material’s matrix. The Examiner considers it prima facie obvious to optimize the degree of hydrolysis, absent unexpectedly superior properties of the claimed invention. In the instant case, one of ordinary skill in the art would have recognized that the degree of hydrolysis would have a direct effect on the stiffness and strength of the hydrogel and therefore be an optimizable variable. Response to Arguments Applicant's arguments filed 6/29/2026 have been fully considered but they are not persuasive. Applicant’s arguments with respect to the rejections over Porter have been considered but are moot because the new ground of rejection does not rely on any reference applied in the prior rejection of record for any teaching or matter specifically challenged in the argument. The Examiner has relied on Ku in the new grounds of rejection for teachings that were not specifically challenged in the arguments, specifically regarding the relationship between PVA molecular weight and tensile strength. Thus, the arguments over Ku in the reply filed 6/29/2026 are moot. Conclusion No claims are allowed. Applicant's amendment necessitated the new ground(s) of rejection presented in this Office action. Accordingly, THIS ACTION IS MADE FINAL. See MPEP § 706.07(a). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a). A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any nonprovisional extension fee (37 CFR 1.17(a)) pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action. Any inquiry concerning this communication or earlier communications from the examiner should be directed to ELIZABETH ANNE MEYERS whose telephone number is (571)272-2271. The examiner can normally be reached Monday-Friday 8am-5pm ET. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Ali Soroush can be reached at 571-272-9925. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. ELIZABETH ANNE MEYERSExaminer, Art Unit 1617 /KATHERINE PEEBLES/Primary Examiner, Art Unit 1617
Read full office action

Prosecution Timeline

Jul 12, 2023
Application Filed
May 15, 2026
Non-Final Rejection mailed — §103
Jun 29, 2026
Response Filed
Sep 10, 2026
Final Rejection mailed — §103
Sep 16, 2026
Interview Requested
Sep 22, 2026
Examiner Interview Summary

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12740974
ORALLY-DISINTEGRATING FILM COMPRISING NARATRIPTAN
3y 3m to grant Granted Sep 22, 2026
Patent 12636244
PERSONAL CARE COMPOSITION CONTAINING A BIOSURFACTANT
2y 7m to grant Granted May 26, 2026
Patent 12514749
EYE LUBRICANT
3y 5m to grant Granted Jan 06, 2026
Study what changed to get past this examiner. Based on 3 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

3-4
Expected OA Rounds
21%
Grant Probability
99%
With Interview (+93.8%)
3y 1m (~0m remaining)
Median Time to Grant
Moderate
PTA Risk
Based on 19 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month